Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMD
NCT00624481 · Nastech Pharmaceutical Company, Inc. · PHASE2 · withdrawn · last registry update 2008-03-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Nastech Pharmaceutical Company, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTH1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2009-02-13Results posted on the registry: Eli Lilly and Company, Teriparatide + Alendronate Sodium (NCT00051558)
- 2008-06-13Phase 3 first posted: Columbia University, Teriparatide (PTH 1-34) (NCT00697463)
- 2008-05-01Phase 3 first posted: Eli Lilly and Company, teriparatide + teriparatide (NCT00670501)
- 2007-12-20Phase 3 first posted: Eli Lilly and Company, teriparatide (NCT00577863)
- 2007-10-12Phase 3 first posted: Eli Lilly and Company, teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneous (NCT00543023)
- 2007-10-12Phase 3 first posted: Eli Lilly and Company, teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneous (NCT00542984)
- 2007-10-12Phase 3 first posted: Eli Lilly and Company, teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneous (NCT00543218)
- 2007-09-20Phase 3 first posted: Eli Lilly and Company, teriparatide (NCT00532207)
- 2007-07-18Phase 3 first posted: Eli Lilly and Company, Teriparatide + Risedronate (NCT00503399)
- 2007-05-15Phase 3 first posted: John P. Bilezikian, PTH (NCT00473265)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision